$MEDE
Medies

2024 Q2 Form 10-Q Financial Statement

#000168316824004846 Filed on July 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2
Revenue $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $6.660K
YoY Change 8.12%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.947K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $6.662K
YoY Change 8.08%
Operating Profit -$6.662K
YoY Change 8.08%
Interest Expense -$170.00
YoY Change -198.84%
% of Operating Profit
Other Income/Expense, Net -$172.00
YoY Change 0.0%
Pretax Income -$6.834K
YoY Change 7.86%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$6.834K
YoY Change 7.86%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 6.667M shares
Diluted Shares Outstanding 6.667M shares

Balance Sheet

Concept 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $400.00
YoY Change -52.94%
Cash & Equivalents $402.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $402.00
YoY Change -52.71%
LONG-TERM ASSETS
Property, Plant & Equipment $20.99K
YoY Change -27.06%
Goodwill
YoY Change
Intangibles $0.00
YoY Change -100.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $20.99K
YoY Change -60.91%
TOTAL ASSETS
Total Short-Term Assets $402.00
Total Long-Term Assets $20.99K
Total Assets $21.39K
YoY Change -60.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $15.06K
YoY Change 1252.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $63.44K
YoY Change 14.37%
Total Short-Term Liabilities $78.50K
YoY Change 38.73%
LONG-TERM LIABILITIES
Long-Term Debt $12.50K
YoY Change 0.0%
Other Long-Term Liabilities $25.50K
YoY Change 0.0%
Total Long-Term Liabilities $38.00K
YoY Change 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $78.50K
Total Long-Term Liabilities $38.00K
Total Liabilities $116.5K
YoY Change 23.17%
SHAREHOLDERS EQUITY
Retained Earnings -$122.7K
YoY Change 81.46%
Common Stock $667.00
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$95.10K
YoY Change
Total Liabilities & Shareholders Equity $21.39K
YoY Change -60.78%

Cashflow Statement

Concept 2024 Q2
OPERATING ACTIVITIES
Net Income -$6.834K
YoY Change 7.86%
Depreciation, Depletion And Amortization $1.947K
YoY Change 0.0%
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities $0.00
Cash From Financing Activities
Net Change In Cash $0.00
YoY Change -100.0%
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures $0.00
Free Cash Flow $0.00
YoY Change -100.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--02-28
CY2024Q2 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
CY2024Q2 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q2 dei Entity Central Index Key
EntityCentralIndexKey
0001918694
CY2024Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
usd
CY2024Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2024Q2 dei Document Type
DocumentType
10-Q
CY2024Q2 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q2 dei Document Period End Date
DocumentPeriodEndDate
2024-05-31
CY2024Q2 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q2 dei Entity File Number
EntityFileNumber
333-264308
CY2024Q2 dei Entity Registrant Name
EntityRegistrantName
MEDIES
CY2024Q2 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WY
CY2024Q2 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1651594
CY2024Q2 dei Entity Address Address Line1
EntityAddressAddressLine1
2100 Geng Road, Suite 210
CY2024Q2 dei Entity Address City Or Town
EntityAddressCityOrTown
Palo Alto
CY2024Q2 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q2 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94303
CY2024Q2 dei City Area Code
CityAreaCode
(650)
CY2024Q2 dei Local Phone Number
LocalPhoneNumber
719-5286
CY2024Q2 dei Security12b Title
Security12bTitle
Common Stock
CY2024Q2 dei Trading Symbol
TradingSymbol
MEDE
CY2024Q2 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q2 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q2 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q2 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q2 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q2 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2024Q2 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6666500 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
402 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
402 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
402 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
402 usd
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0 usd
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20992 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22939 usd
CY2024Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
20992 usd
CY2024Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
22939 usd
CY2024Q2 us-gaap Assets
Assets
21394 usd
CY2024Q1 us-gaap Assets
Assets
23341 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15056 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10169 usd
CY2024Q2 MEDE Loans From Related Parties Current1
LoansFromRelatedPartiesCurrent1
63440 usd
CY2024Q1 MEDE Loans From Related Parties Current1
LoansFromRelatedPartiesCurrent1
63440 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
78496 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
73609 usd
CY2024Q2 MEDE Notes Payable Related Party Noncurrent1
NotesPayableRelatedPartyNoncurrent1
12500 usd
CY2024Q1 MEDE Notes Payable Related Party Noncurrent1
NotesPayableRelatedPartyNoncurrent1
12500 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
25500 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
25500 usd
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
38000 usd
CY2024Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
38000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
116496 usd
CY2024Q1 us-gaap Liabilities
Liabilities
111609 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6666500 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6666500 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6666500 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6666500 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
667 usd
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
667 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
26899 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
26899 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122668 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-115834 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-95102 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-88268 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21394 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23341 usd
CY2024Q2 us-gaap Revenues
Revenues
0 usd
CY2023Q2 us-gaap Revenues
Revenues
0 usd
CY2024Q2 us-gaap Gross Profit
GrossProfit
0 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
0 usd
CY2024Q2 us-gaap Professional Fees
ProfessionalFees
4715 usd
CY2023Q2 us-gaap Professional Fees
ProfessionalFees
695 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1947 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5469 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
6662 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
6164 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
172 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
172 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-172 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-172 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6834 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6336 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-6834 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6336 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6666500 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6666500 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6666500 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6666500 shares
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-88268 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-6834 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-95102 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-33698 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6336 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-40034 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-6834 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6336 usd
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3265 usd
CY2024Q2 us-gaap Depreciation
Depreciation
1947 usd
CY2023Q2 us-gaap Depreciation
Depreciation
1947 usd
CY2024Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4887 usd
CY2023Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
112 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1012 usd
CY2024Q2 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
-0 usd
CY2023Q2 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
-0 usd
CY2024Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2024Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2024Q2 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
CY2023Q2 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
CY2024Q2 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
CY2023Q2 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
0 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1012 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
402 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1862 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
402 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
850 usd
CY2024Q2 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q2 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2024Q2 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q2 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122668 usd
CY2024 us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
CY2024Q2 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84D_eus-gaap--UseOfEstimates_z8i7ZvlZxUTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates and Assumptions</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the limited level of operations, the Company has not had to make material assumptions or estimates other than the assumption that the Company is a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q1 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
38930 usd
CY2024Q2 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
CY2024Q2 us-gaap Depreciation
Depreciation
1947 usd
CY2023Q2 us-gaap Depreciation
Depreciation
1947 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
20994 usd
CY2024 us-gaap Adjustment For Amortization
AdjustmentForAmortization
13060 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
24057 usd
CY2024 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
15123 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6666500 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6666500 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6666500 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6666500 shares
CY2024Q2 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
1435 usd
CY2024 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
24325 usd
CY2024Q2 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-1435 usd
CY2024 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-24325 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1435 usd
CY2024Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
24325 usd
CY2024Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1435 usd
CY2024Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
24325 usd
CY2024Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2024Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2024Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
122668 usd
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-004846-index-headers.html Edgar Link pending
0001683168-24-004846-index.html Edgar Link pending
0001683168-24-004846.txt Edgar Link pending
0001683168-24-004846-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
mede-20240531.xsd Edgar Link pending
mediesi10q-053124.htm Edgar Link pending
medies_ex3101.htm Edgar Link pending
medies_ex3102.htm Edgar Link pending
medies_ex3201.htm Edgar Link pending
medies_ex3202.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
mede-20240531_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
mede-20240531_def.xml Edgar Link unprocessable
mede-20240531_lab.xml Edgar Link unprocessable
mede-20240531_pre.xml Edgar Link unprocessable
mediesi10q-053124_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending